pharmaphorum

NOVEMBER 23, 2021

Sanofi is the first pharma company to partner with Baidu on its LinearDesign AI platform, which has been developed specifically to optimise the sequence of mRNA-based vaccines and drugs. billion earlier this year. Specific financial terms have not been disclosed.

Licensing 104

Licensing Licensing Vaccination Vaccine 104

The Pharma Data

DECEMBER 11, 2020

The University of Oxford has regularly appeared in our updates since July 2020, as its team of researchers leads an ongoing clinical trial for the Covid-19 vaccine. More recently, the university has released news of its collaboration with Thermo Fisher Scientific as it looks to discover an immune Covid-19 response pre- and post-vaccination.

Antibody 52

Antibody Vaccination Vaccine Containment 52

pharmaphorum

SEPTEMBER 23, 2021

AstraZeneca has joined the ranks of big pharma companies bolting on RNA-based technology platforms in the wake of the stellar success of mRNA vaccines for COVID-19. The company sees its deal with VaxEquity as going well beyond COVID-19, extending into other vaccines as well as therapeutic drugs.

RNA 52

RNA Immune Response Vaccination Vaccine 52

The Pharma Data

NOVEMBER 27, 2020

Vaccine development to cure coronavirus is at an all-time high after Pfizer and BioNTech announced they had success with a possible vaccine candidate. One dose of the Sputnik V vaccine will cost less than $10 for international markets.

Vaccination 52

Vaccination Vaccine Immune Response Marketing 52

pharmaphorum

SEPTEMBER 20, 2022

Ben Hargreaves highlights the innovation in vaccine delivery that could make a difference in providing low- and middle-income countries with vaccination options, as well as offer a boost to programs in higher-income countries. The question to be answered in the future will be how to improve upon existing vaccine technology.

Vaccination 94

Vaccination Vaccine Immune Response Antibody 94

XTalks

SEPTEMBER 5, 2023

Vaccines have been an integral piece of the global public health toolbox for over 200 years, but the COVID-19 pandemic brought about a new era in vaccine development with renewed interest in mRNA technology and unprecedented accelerated regulatory approvals. What are the major challenges you’re facing right now in vaccine development?

Vaccination 96

Vaccination Vaccine Development Clinical Trials 96

pharmaphorum

AUGUST 13, 2020

In 2018 the research firm Reputation Institute ranked Pfizer’s reputation at rock bottom on a list of 22 pharma companies – and none of them ranked highly against other sectors! Pfizer has four different mRNA platform vaccines in play against one-another: a radical new approach for them.

Branding 90

Branding Vaccination Vaccine Filler 90

XTalks

AUGUST 17, 2020

chimeric receptor antigen [CAR] T cell) immune modulators (i.e. protein-based biologics) and vaccine treatments. Immune checkpoint inhibitors : these are drugs that block immune checkpoints, allowing immune cells to elicit enhanced responses to cancer cells. Immune system modulators (i.e.

Protein 98

Protein Engineer Immune Response In-Vivo 98

Drug Discovery World

MAY 6, 2024

As companies move through the phases of development, they benefit from a long-established ecosystem of competency in clinical regulation. So, in this way there is a cross fertilisation from the bigger companies to newer ones. More than 400 companies now make up Lithuania’s life sciences sector 4.

Drugs 59

Drugs Life Science Gene Editing Gene 59

Drug Discovery World

APRIL 20, 2023

Symptoms affect the brain, heart, lungs, GI tract and pancreas, are seen equally in vaccinated populations, and sometimes newly emerge after the acute infection has resolved. Given the numbers involved, these persistent symptoms likely represent great future challenges for healthcare systems. Alzheimer’s disease), or by initiating a new one.

Development 98

Development Drugs Clinical Trials Clinical Trials 98

XTalks

AUGUST 18, 2021

While infectious disease experts and drug companies have rightfully spent the last 18 months developing therapeutics and vaccines targeting SARS-CoV-2 and COVID-19, another global threat to public health — antimicrobial resistance (AMR) — has, and will continue to, persist until similar direct action is taken. That is, until now.

Development 105

Development Bacteria Drugs Vaccination 105

World of DTC Marketing

AUGUST 6, 2020

million people have been infected and nearly 155,000 have died, the promise of that vaccine is hampered by a vexing epidemic that long preceded Covid-19: obesity. Of course, there is no ROI in providing people with health information that can use but it would show that pharma companies are interested in the welfare of people versus profits.

Doctors 180

Doctors Doctor Immune Response Vaccination 180

World of DTC Marketing

SEPTEMBER 28, 2020

J&J’s COVID vaccine is being promoted by the media to have a 98% immune system response. Will it lead to an early approval with limited testing or will J&J ensure the vaccine goes thru thorough testing? government to manufacture 100 million doses of its investigational COVID-19 vaccine.

Vaccination 163

Vaccination Vaccine Clinical Trials Clinical Trials 163